Navigation Links
Calando in Medical Technology

Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA

PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - Arrowhead Research Corporation (NASDAQ:ARWR) announced today that majority-owned subsidiary Calando Pharmaceuticals has published results in the Proceedings of the National Academy of Sciences (PNAS) of the first non-human primate study to use multi...

Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

PASADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 - Arrowhead Research Corporation (NASDAQ: ARWR) announced the publication by its majority-owned subsidiary Calando Pharmaceuticals, Inc. of a study demonstrating the anti-proliferative effect of the siRNA sequence selected as the therapeutic component ...

Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting

Novel Systems May Provide Cancer Patients With Improved Potential to Battle Their Disease PASADENA, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Arrowhead Research Corporation announced today that two of its majority-owned subsidiaries, Insert Therapeutics Inc. and Calando Pharmaceuticals Inc....

Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal

...s to cause highly targeted gene silencing. About calando Pharmaceuticals Inc. calando Pharmaceuticals Inc. (www.calandopharma.com), a ma...with pharmaceutical and biotechnology companies. calando Technology Calando's cyclodextrin-containing pol...

Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

...f Cancer Research (AACR). This paper describes how calando researchers and their collaborators determined the...Chief Executive Officer. Petrovich also noted that calando has filed for patent protection on several siRNA d...s to cause highly targeted gene silencing. About calando Pharmaceuticals Inc. ...

Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting

...," said Jeremy Heidel, Chief Scientific Officer at calando Pharmaceuticals. "This formulation was well-tolera... cells has also been accomplished in vivo. About calando Pharmaceuticals Inc. calando Pharmaceuticals Inc. (
(Date:8/21/2014)... WHEN: , Saturday to Wednesday, Oct. 18-22, 2014 ... 111 W. Harbor Drive, San Diego, CA 92101 ... sessions and other presentations of the latest research ... Opening plenary session featuring high-scoring abstracts on rare ... of various cancers, and treatment for sun sensitivity ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3American Society of Human Genetics 2014 Annual Meeting 2
Other Contents